sabato, 13 luglio 2024
5 Luglio 2019

FDA Approves Avatrombopag in Chronic ITP

July 1, 2019 – The FDA has approved a supplemental new drug application (sNDA) to expand the use of avatrombopag to include the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to prior therapy. The approval of the oral thrombopoietin receptor agonist is mostly based on findings from a phase III trial, which demonstrated that avatrombopag led to a platelet count of >50,000 per µL after 8 days of therapy in the … (leggi tutto)